Search results for: d842V

15 05, 2020

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

By |2020-05-15T10:10:47-04:00May 15th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.

9 01, 2020

Breaking News for GIST Patients – Avapritinib Approved!

By |2020-01-10T16:06:14-05:00January 9th, 2020|News|

Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

7 08, 2019

Blueprint Medicines Announces Next Step for Avaprinitib

By |2019-08-07T13:24:21-04:00August 7th, 2019|Drug Treatment, News|

Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]

20 06, 2019

New Horizons – International Focus on the Power of Real World Data to Enhance Advocacy Efforts

By |2020-07-15T14:51:55-04:00June 20th, 2019|Advocacy, Global, News, Newsletter|

International advocates meet in Wayne, NJ, at the annual New Horizons GIST Conference to discuss scientific updates, regional issues, and unmet needs for the global GIST community in May 2019.

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top